FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.
News|Articles|March 3, 2026
Legislative roundup: VBMs, ODs clash in HB 1696 lawsuit; safety alert issued for vision-testing kiosk in Pennsylvania
Author(s)Jordana Joy, Editor
Learn the latest on legislative updates from Arkansas, Texas, South Carolina, and Pennsylvania.
Advertisement
Advertisement
It has already been a busy year legislatively thus far for eye care providers across the country. From the striking down of house bills to the issuance of safety alerts, here are the latest legislative updates that pertain to optometrists:
Related to this article
Amanda Nanasy, OD, described how her own concussion shaped her approach to athletes and why she ties every vision evaluation back to the demands of their sport.
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
IDOC's 2025 benchmarks from 175-plus independent OD practices put median practice net at 31% of revenue as variable costs fell for the first time since tracking began.
A handful of eye care providers spoke on the factors that have led to a lack of eye care access for World Sight Day.
Advertisement
Advertisement